Livzon Pharmaceutical : POLL RESULTS OF THE 2021 SECOND EXTRAORDINARY GENERAL MEETING HELD ON THURSDAY, 6 MAY 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

POLL RESULTS OF

THE 2021 SECOND EXTRAORDINARY GENERAL MEETING

HELD ON THURSDAY, 6 MAY 2021

References are made to the notice and circular (the "Circular") of the 2021 second extraordinary general meeting (the "EGM") of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.＊(the "Company") dated 9 April 2021 and 15 April 2021, respectively. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the proposed resolutions as set out in the notice of the EGM were duly passed by way of poll at the EGM held on 6 May 2021.

As at the record date of the EGM, the issued share capital of the Company was 939,778,299 shares (the "Shares") (comprising 619,914,082 A Shares and 319,864,217 H Shares). Therefore, Shareholders holding a total of 939,778,299 Shares (or the authorized proxies) were entitled to attend and vote on the resolutions proposed at the EGM.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, there were no restrictions on any Shareholders for casting votes on the resolutions proposed at the EGM and none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the EGM. No Shareholders are required under the Hong Kong Listing Rules to abstain from voting on the resolutions at the EGM.

1

ATTENDANCE OF THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies

Including: Number of A Shareholders and authorized proxies

Number of H Shareholders and authorized proxies

Total number of Shares carrying voting rights (Shares)

Including: Total number of A Shares carrying voting rights held by A Shareholders and authorized proxies (Shares)

Total number of H Shares carrying voting rights held by H

Shareholders and authorized proxies (Shares)

51

50

1

505,901,751

288,937,921

216,963,830

Percentage of the total number of Shares carrying voting rights (%)	53.83%
Including: Total number of Shares carrying voting rights held by A Shareholders and authorized	30.75%
proxies as a percentage of the total number of Shares carrying voting rights (%)
Total number of Shares carrying voting rights held by H Shareholders and authorized	23.09%
proxies as a percentage of the total number of Shares carrying voting rights (%)

2

POLL RESULTS OF THE EGM- SEPCIAL RESOLUTIONS

For

Against

Abstain

Number of

Percentage

Percentage

Percentage

(%) of

(%) of

(%) of

Shares with

number of

number of

number of

Category

voting rights

Shares with

Shares with

Shares with

No.

Resolutions

held by

Number of

Number of

Number of

of Shares

voting rights

voting rights

voting rights

Shareholders

Shares

Shares

Shares

held by

held by

held by

present at the

Shareholders

Shareholders

Shareholders

meeting

present at the

present at the

present at the

meeting

meeting

meeting

To consider and approve the draft

Total

505,901,751

446,577,228

88.2735%

59,323,923

11.7264%

600

0.0001%

and summary of the first phase

1

ownership

scheme

under

the

A Shares

288,937,921

264,609,529

91.5801%

24,327,792

8.4197%

600

0.0002%

Medium to Long-term

Business

Partner Share Ownership Scheme

of the Company.

H Shares

216,963,830

181,967,699

83.8701%

34,996,131

16.1299%

0

0.0000%

To

consider

and

approve

the

Total

505,901,751

445,558,087

88.0721%

60,343,664

11.9279%

0

0.0000%

administrative

measures of

the

first

phase

ownership

scheme

A Shares

288,937,921

263,591,388

91.2277%

25,346,533

8.7723%

0

0.0000%

2

under the Medium to Long-term

Business

Partner

Share

H Shares

216,963,830

181,966,699

83.8696%

34,997,131

16.1304%

0

0.0000%

Ownership

Scheme

of

the

Company.

To

consider

and approve at

the

Total

505,901,751

445,639,987

88.0882%

60,261,164

11.9116%

600

0.0001%

general

meeting

for

granting

mandate to the board of directors

A Shares

288,937,921

263,571,588

91.2208%

25,365,733

8.7790%

600

0.0002%

of the

Company to deal with

3

matters regarding the first phase

ownership

scheme

under

the

H Shares

216,963,830

182,068,399

83.9165%

34,895,431

16.0835%

0

0.0000%

Medium to Long-term

Business

Partner Share Ownership Scheme

of the Company.

As votes cast for the above special resolutions were more than two-thirds of the valid voting rights of Shareholders (including authorized proxies) present at the EGM, the above

special resolutions were duly passed as the special resolutions.

3

Grant Thornton (Special General Partnership), the auditor of the Company, acted as the scrutineer for the vote- taking at the EGM. The Company's PRC legal advisors, D&S Law Firm ( 廣 東 德 賽 律 師 事 務 所 ), two Shareholders' representatives and a representative of the supervisors of the Company also jointly acted as the scrutineers for the vote-taking of the poll at the EGM.

LEGAL OPINION ISSUED BY LAWYERS

Delegated lawyers from D&S Law Firm witnessed the EGM and issued the "Legal Opinions of D&S Law Firm on the EGM of Livzon Pharmaceutical Group Inc. (《 廣東德賽律師事務所關於麗珠醫藥集團股份有限公司二零 二一年第二次臨時股東大會的法律意見書》 )", certifying that: "The procedures for convening and holding the EGM are in compliance with the requirements of laws, regulations and Articles of Association; the qualifications of personnels who attended the EGM, the qualifications of the conveners, and the voting procedure of the EGM are legal and effective; the voting results of the resolutions at the EGM, are legal and effective. "

SPECIAL NOTICE

There was neither objection to the proposed resolutions of the EGM, nor changes to the resolutions of the previous general meetings at the EGM.

By order of the Board

麗珠醫藥集團股份有限公司

Livzon Pharmaceutical Group Inc. *

Yang Liang

Company Secretary

Zhuhai, China

6 May 2021

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

* For identification purpose only

4